Qube Research & Technologies (QRT)
KALV

Qube Research & Technologies (QRT)’s KalVista Pharmaceuticals KALV Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-180,314
Closed -$3.63M – 3794
2026
Q1 		$3.63M Buy
+180,314
New +$2.91M ﹤0.01% 1828
2025
Q4 		– Sell
-325,435
Closed -$3.96M – 3883
2025
Q3 		$3.96M Buy
325,435
+228,187
+235% +$3.15M ﹤0.01% 1894
2025
Q2 		$1.1M Buy
+97,248
New +$1.19M ﹤0.01% 2425
2025
Q1 		– Sell
-126,132
Closed -$1.07M – 3696
2024
Q4 		$1.07M Sell
126,132
-52,476
-29% -$543K ﹤0.01% 2139
2024
Q3 		$2.07M Buy
178,608
+149,019
+504% +$1.87M ﹤0.01% 1752
2024
Q2 		$349K Sell
29,589
-149,149
-83% -$1.74M ﹤0.01% 2259
2024
Q1 		$2.12M Buy
+178,738
New +$2.38M ﹤0.01% 1720
2021
Q2 		– Sell
-21,030
Closed -$540K – 2541
2021
Q1 		$540K Buy
+21,030
New +$553K 0.01% 1135

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Qube Research & Technologies (QRT)'s KALV Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 180,314 shares — an estimated $3.63M sold.

Qube Research & Technologies (QRT) first reported a position in KALV in Q1 2021 and held it in 8 quarters. The position peaked at $3.96M in Q3 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 180,314 KalVista Pharmaceuticals shares in Q2 2026, an estimated $3.63M.
  • Qube Research & Technologies (QRT) first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Qube Research & Technologies (QRT)'s KalVista Pharmaceuticals position peaked at $3.96M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.